Description:

Z1031: Extended Follow-up Form Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FAD6C4E6-87C2-1268-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FAD6C4E6-87C2-1268-E034-0003BA3F9857

Keywords:
Versions (2) ▾
  1. 8/27/12
  2. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Endometrial Cancer NCT00265759 Follow-Up - Z1031: Extended Follow-up Form - 2316464v3.0

No Instruction available.

  1. StudyEvent: Z1031: Extended Follow-up Form
    1. No Instruction available.
Header Module
Visit
Header
Vital status
Primary cause of death (If deceased,)
Was imaging done to assess for recurrence (Mam, U/S, MRI, etc.)
Notice Of First Recurrence/progression
Has the patient developed a first progression (or relapse) that has not been previously reported?
First recurrence/progression
Site of first recurrence/progression
Notice Of New Primary
Has a new primary cancer or MDS been diagnosed that has not been previously reported?
Footer Module

Similar models